Ask AI
ProCE Banner Activity

HBV Reactivation and ART, a Growing Concern: What Did We Learn at IAS 2025?

Conference Coverage
Clinical Thought

Despite progress in hepatitis B virus (HBV) prevention, a high burden of HBV and HIV coinfection persists in the European region. Read on to learn what experts at IAS 2025 had to say about how an antiretroviral therapy switch to HBV-inactive regimens could affect the rate of HBV reactivation in people living with HIV and HBV coinfection.

Released: August 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with the International AIDS Society.

 
ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner

Disclosure

Primary Author

Laura J. Waters, FRCP, MD: consultant/advisor/speaker: Janssen, Merck, ViiV; researcher: Gilead, Merck.